Puma Biotechnology's NERLYNX(r) Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Source :: Plus Company Updates. December 26, 2024
Publication Year :: 2024
Abstract: LOS ANGELES: PUMA BIOTECHNOLOGY, INC. has issued the following news release: Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines [...]

Subjects :: National Comprehensive Cancer Network
Drug therapy
Genetic aspects
Cancer treatment
Biotechnology -- Genetic aspects
Cervical cancer -- Genetic aspects -- Drug therapy
Practice guidelines (Medicine)
Neratinib
Cancer -- Care and treatment

Tools